Nancy U Lin

56PUBLICATIONS
379CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityImmunogenetics (incl. genetic immunology)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (56)

|Jun 05, 2026
Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

|May 15, 2026
Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial.

|Mar 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results.

Rashmi K Murthy, Barbara J O'Brien, Donald A Berry

|Mar 07, 2026
A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.

Antonio Giordano, Noah Graham, Ayal A Aizer

|Nov 21, 2025
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

Daniel Kates-Harbeck, Hans Kreipe, Oleg Gluz

|Sep 04, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.

Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder

Pageof 10

Frequent Collaborators

13 joint publications

Sara M Tolaney

13 joint publications

Eric Winer

9 joint publications

Elizabeth Mittendorf

6 joint publications

Ian E Krop